公开(公告)号：EP4245302A1

公开(公告)日：2023-09-20

申请号：EP22162072.7

申请日：2022-03-15

申请人： Charité - Universitätsmedizin Berlin

发明人： Kübler, Wolfgang ,  Simmons, Szandor ,  Asmus, Erik ,  Szulcek, Robert ,  Preißner, Robert

IPC分类号： A61K31/404 ,  A61K31/443 ,  A61K31/47 ,  A61P7/02 ,  A61K31/4439

摘要： The invention relates to the field of pharmaceutical compositions and the treatment and/or prevention of medical conditions comprising thrombosis, or atherosclerosis associated with pathological thrombocyte activation. The invention further relates to a cystic fibrosis transmembrane conductance regulator (CFTR) modulator for use in the treatment and/or prevention of a medical condition comprising thrombosis, or a medical condition comprising atherosclerosis and pathological thrombocyte activation, in a human subject. The invention further relates to the medical use and corresponding therapeutic methods of administering a CFTR modulator, such as ivacaftor, in the treatment and/or prevention of a medical condition pathological thrombocyte activation, adhesion and/or aggregation. In further aspects, the invention relates to a pharmaceutical composition comprising a CFTR modulator, such as ivacaftor.